Corvus Pharmaceuticals (CRVS) to Post Quarterly Earnings on Thursday

Key Points

• Corvus Pharmaceuticals is expected to report Q2 2026 earnings before the market opens Thursday, August 6. Analysts anticipate a loss of $0.17 per share; the earnings call is scheduled for 4:30 p.m. ET.
• The company reported a Q1 loss of $0.15 per share, missing the $0.14 consensus estimate. Analysts project losses of approximately $1 per share for both the current and next fiscal years.
• CRVS shares opened at $13.04, down 2%, while analysts maintain a “Moderate Buy” consensus rating with an average price target of $33.33. A company director recently purchased 21,700 shares, and insiders own 19.7% of the stock.

Corvus Pharmaceuticals (NASDAQ:CRVS - Get Free Report) is expected to be announcing its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect Corvus Pharmaceuticals to announce earnings of ($0.17) per share for the quarter. Investors can check the company's upcoming Q2 2026 earning report page for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:30 PM ET.

Corvus Pharmaceuticals (NASDAQ:CRVS - Get Free Report) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.01). On average, analysts expect Corvus Pharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Corvus Pharmaceuticals Stock Down 2.0%

Shares of CRVS opened at $13.04 on Thursday. Corvus Pharmaceuticals has a twelve month low of $3.96 and a twelve month high of $26.95. The stock has a market capitalization of $1.10 billion, a P/E ratio of -25.08 and a beta of 0.82. The company has a 50 day moving average of $13.28 and a 200-day moving average of $15.07.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the stock. Weiss Ratings raised shares of Corvus Pharmaceuticals from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Tuesday. The Goldman Sachs Group started coverage on shares of Corvus Pharmaceuticals in a research note on Friday, April 17th. They set a "buy" rating and a $40.00 price objective for the company. Finally, Wall Street Zen cut Corvus Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Saturday, May 9th. Six investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $33.33.

Insider Transactions at Corvus Pharmaceuticals

In other news, Director David Scott Moore bought 21,700 shares of the business's stock in a transaction that occurred on Thursday, June 11th. The stock was acquired at an average cost of $11.53 per share, for a total transaction of $250,201.00. Following the purchase, the director owned 21,700 shares of the company's stock, valued at approximately $250,201. This trade represents a ∞ increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 19.70% of the company's stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in CRVS. Quarry LP bought a new stake in shares of Corvus Pharmaceuticals during the third quarter worth approximately $27,000. Russell Investments Group Ltd. bought a new position in shares of Corvus Pharmaceuticals during the third quarter worth approximately $49,000. Sender Co & Partners Inc. bought a new position in shares of Corvus Pharmaceuticals during the second quarter worth approximately $52,000. Bayesian Capital Management LP acquired a new stake in Corvus Pharmaceuticals during the 2nd quarter worth approximately $70,000. Finally, The Manufacturers Life Insurance Company acquired a new stake in Corvus Pharmaceuticals during the 2nd quarter worth approximately $76,000. 46.64% of the stock is currently owned by institutional investors.

About Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation immuno-oncology therapies. The company's research efforts are centered on harnessing both the innate and adaptive immune systems to counteract tumor-driven immunosuppression. By targeting key pathways that regulate immune cell function, Corvus aims to create novel agents that can be combined with existing cancer treatments to improve patient outcomes.

Corvus's lead pipeline candidates include small-molecule and antibody therapies designed to inhibit the adenosine pathway, a known mediator of tumor immune escape.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.